For
the three months ended March 31, 2026 and 2025, the following securities from net loss per share have been excluded as the effect of
including them would have been anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| | |
| | |
| |
| | |
March 31, | |
| (in millions) | |
2026 | | |
2025 | |
| Outstanding options exercisable | |
| 0.6 | | |
| 0.7 | |
| Nonvested restricted and performance stock units | |
| 7.1 | | |
| 12.4 | |
| Shares of common stock that may be issued through conversion of the derivative liability | |
| 72.8 | | |
| 20.5 | |
| Shares of common stock that may be issued through the exercise of warrants | |
| 5.8 | | |
| 5.8 | |
| Antidilutive securities excluded from computation of earnings per share, amount | |
| 5.8 | | |
| 5.8 | |
|